Adrian Gottschalk
Fortune : 2 M $ au 31/05/2026
Fortune : 2 M $ au 31/05/2026
Adrian Gottschalk is President, Chief Executive Officer & Director at Foghorn Therapeutics, Inc. since 2017.
Formerly, Mr. Gottschalk was SVP & Head-Neurodegeneration Therapeutic Area at Biogen, Inc. from 2015 to 2017.
Education includes an undergraduate degree from Texas A&M University in 1997, an MBA from MIT Sloan School of Management in 2003, and a graduate degree from Harvard Medical School in 2004.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 20/04/2026 | 511 704 ( 0,87% ) | 2 M $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| FOGHORN THERAPEUTICS INC. | Directeur Général | 01/05/2017 |
| Sociétés | Poste | Fin |
|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | 01/05/2017 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 5 |
|---|---|
Biogen, Inc.
Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Texas A&M University
Texas A&M University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Medical School
Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MIT Sloan School of Management
MIT Sloan School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Foghorn Therapeutics, Inc.
Foghorn Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops novel drugs to treat cancer and other serious medical disorders | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national